by Jakub Jarolím, Business Intelligence Department
Dear customer, we are sorry but your browser doesn't support all necessary features for good site view. Please switch to one of the modern browsers (Chrome, Safari, Firefox).
Sotio Biotech
3/10/2022
September 2022 Biotechnology: Review of news from the most innovative therapeutic areas and the business development transactions
Market
Entrenching inflation and hiking interest rates result in S&P 500 index falling by 9%
September is usually a bad month for investors, with this September S&P 500 fell by more than 9%. This the worst September since 2002, when S&P 500 fell by 11%. The NBI dropped by 3%. There are worrisome signs that inflation is becoming more entrenched, which will make it harder to contain.
Antibody-Drug Conjugates
EMA’s CHMP recommended Zynlonta for approval for treatment of DLBCL
News detail
Interleukin-15 and Interleukin-2
Medicenna reported confirmed partial response in pancreatic cancer in Phase 1/2
Medicenna Therapeutics announced new clinical data on anti-tumor activity from the Phase 1/2 ABILITY study of MDNA11. These data include a confirmed partial response in a fourth-line metastatic pancreatic ductal adenocarcinoma patient that had previously failed chemo and checkpoint inhibitor therapies.
Share on social networks